Synthesis and Preclinical Evaluation of a Novel Fluorine-18-Labeled Tracer for Positron Emission Tomography Imaging of Bruton’s Tyrosine Kinase
ACS Pharmacology & Translational Science · 2023-03-10 · 6 (3) · 410-421
DOI: 10.1021/acsptsci.2c00215 ↗At a glance
Journal article in ACS Pharmacology & Translational Science, published online on 2023-02-10. Written by Kaixuan Li and 12 co-authors. Institution: Center for Advanced Study of Drug Action and Department of Chemistry, Stony Brook University, John S. Toll Drive, Stony Brook, New York 11794-3400, U…. Cited 11 times so far (Crossref); 42 references. The full text is freely available in PubMed Central. Funded by: NIBIB NIH HHS, NIGMS NIH HHS, National Institute of Biomedical Imaging and Bioengineering.
Abstract (original language)
Bruton's tyrosine kinase (BTK) is a target for treating B-cell malignancies and autoimmune diseases. To aid in the discovery and development of BTK inhibitors and improve clinical diagnoses, we have developed a positron emission tomography (PET) radiotracer based on a selective BTK inhibitor, remibrutinib. [18F]PTBTK3 is an aromatic, 18F-labeled tracer that was synthesized in 3 steps with a 14.8 ± 2.4% decay-corrected radiochemical yield and ≥99% radiochemical purity. The cellular uptake of [18F]PTBTK3 was blocked up to 97% in JeKo-1 cells using remibrutinib or non-radioactive PTBTK3. [18F]PTBTK3 exhibited renal and hepatobiliary clearance in NOD SCID (non-obese diabetic/severe combined immunodeficiency) mice, and the tumor uptake of [18F]PTBTK3 in BTK-positive JeKo-1 xenografts (1.23 ± 0.30% ID/cc) was significantly greater at 60 min post injection compared to the tumor uptake in BTK-negative U87MG xenografts (0.41 ± 0.11% ID/cc). In the JeKo-1 xenografts, tumor uptake was blocked up to 62% by remibrutinib, indicating the BTK-dependent uptake of [18F]PTBTK3 in tumors.
Authors and institutions
- Center for Advanced Study of Drug Action and Department of Chemistry, Stony Brook University, John S. Toll Drive, Stony Brook, New York 11794-3400, United States.
- Enzymlogic S.L., QUBE Technology Park, C/Santiago Grisolía, 2, 28760 Madrid, Spain.
- Department of Psychiatry, Department of Radiology, Department of Medicine, Stony Brook Cancer Center, and Facility of Experimental Radiopharmaceutical Manufacturing (FERM), Stony Brook Renaissance School of Medicine, St…
ORCID profiles: Wenchao Qu, Peter J Tonge
Funding
- NIBIB NIH HHS
- NIGMS NIH HHS
- National Institute of Biomedical Imaging and Bioengineering
- Stony Brook University
Cite
APA
Li, K., Wang, M., Akoglu, M., Pollard, A. C., Klecker, J. B., Alfonso, P., Corrionero, A., Prendiville, N., Qu, W., Parker, M. F. L., Turkman, N., Cohen, J. A., & Tonge, P. J. (2023). Synthesis and Preclinical Evaluation of a Novel Fluorine-18-Labeled Tracer for Positron Emission Tomography Imaging of Bruton’s Tyrosine Kinase. ACS Pharmacology & Translational Science, 6(3), 410-421. https://doi.org/10.1021/acsptsci.2c00215
Vancouver
Li K, Wang M, Akoglu M, Pollard AC, Klecker JB, Alfonso P, et al. Synthesis and Preclinical Evaluation of a Novel Fluorine-18-Labeled Tracer for Positron Emission Tomography Imaging of Bruton’s Tyrosine Kinase. ACS Pharmacology & Translational Science. 2023;6(3):410-421. doi:10.1021/acsptsci.2c00215
BibTeX
@article{Li2023,
author = {Li, Kaixuan and Wang, Mingqian and Akoglu, Melike and Pollard, Alyssa C and Klecker, John B and Alfonso, Patricia and Corrionero, Ana and Prendiville, Niall and Qu, Wenchao and Parker, Matthew F L and Turkman, Nashaat and Cohen, Jules A and Tonge, Peter J},
title = {Synthesis and Preclinical Evaluation of a Novel Fluorine-18-Labeled Tracer for Positron Emission Tomography Imaging of Bruton’s Tyrosine Kinase},
journal = {ACS Pharmacology & Translational Science},
year = {2023},
volume = {6},
number = {3},
pages = {410--421},
doi = {10.1021/acsptsci.2c00215}
}
EUVIMED